Soap,,Fresh,Softsoap,Beauty Personal Care , Skin Care , Body,Hand,fl,11.25,hiteknova.com,Antibacterial,-,$1,Citrus,Liquid,/pyrope175922.html Soap,,Fresh,Softsoap,Beauty Personal Care , Skin Care , Body,Hand,fl,11.25,hiteknova.com,Antibacterial,-,$1,Citrus,Liquid,/pyrope175922.html $1 Softsoap Antibacterial Liquid Hand Soap, Fresh Citrus - 11.25 fl Beauty Personal Care Skin Care Body Softsoap Antibacterial Liquid Hand Soap Fresh Citrus - Store 11.25 fl Softsoap Antibacterial Liquid Hand Soap Fresh Citrus - Store 11.25 fl $1 Softsoap Antibacterial Liquid Hand Soap, Fresh Citrus - 11.25 fl Beauty Personal Care Skin Care Body

Softsoap Antibacterial Liquid Hand Soap Fresh Regular dealer Citrus - Store 11.25 fl

Softsoap Antibacterial Liquid Hand Soap, Fresh Citrus - 11.25 fl

$1

Softsoap Antibacterial Liquid Hand Soap, Fresh Citrus - 11.25 fl

|||

Product description

Wash away dirt and bacteria with Softsoap Fresh Citrus Antibacterial Hand Soap. This unique formula contains moisturizers to leave your skin feeling soft and protected. It also gently cleans and protects your hands by helping to eliminate 99.9% of bacteria (based on a handwashing test vs the following common harmful bacteria: S. aureus amp; E. coli). The fresh and citrus scent, made with oils and extracts, heightens the hand washing experience, making this hand soap the perfect addition to any kitchen or bathroom. Due to its unique formula, this hand soap pump should only be refilled with Softsoap Antibacterial Liquid Hand Soap.


From the manufacturer

Softsoap Antibacterial Liquid Hand Soap, Fresh Citrus - 11.25 fl

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA